IGI Logo

India’s fertility market is witnessing robust growth and GAUDIUMI is wellpositioned to capitalise on the increasing demand through an aggressive expansion strategy and differentiated clinical outcome. We met the management of GAUDIUMI, Dr. Manika Khanna - Promoter & CMD and Mr. Rakesh Kumar Sharma - CFO. Additionally, we visited the company's Janakpuri hospital.

GAUDIUMI plans to significantly expand its network in the next two years by increasing its footprint, from 7 hubs and 28 spokes to approximately 26 hubs and nearly 100 spokes. This strategy is aimed at strengthening the company's pan-India presence and making fertility treatment more accessible to patients across the country. The company also has a strong international presence, with around 25% of its patient base coming from nearly 30 countries. GAUDIUMI continues to demonstrate strong clinical outcome, achieving an IVF first-cycle success rate of ~58% and a cumulative pregnancy success rate of ~85% within three treatment cycles

Expansion Strategy

* The company follows a capital-efficient hub-and-spoke model where fully equipped IVF hubs perform critical procedures while spoke centers mainly handle patient acquisition, counselling, diagnostics and initial treatment

* The management plans to expand, from 7 hubs and 28 spokes to approximately 26 hubs and nearly 100 spokes within the next two years, funded primarily through IPO proceeds. The objective is to strengthen its presence across India while improving accessibility of fertility treatment

* The plan is to start 10 hubs in FY27, of which 3 already started in Q1FY27 and introducing 25-bedded only-women hospital in Lucknow

* The company is actively strengthening its international presence by expanding spoke centers in countries, such as UK, France, and Nigeria. These centers primarily serve as patient acquisition channels for medical tourism, bringing international patients to India for treatment

* ~25% of patients currently come from international patients across nearly 30 countries. These international patients generate revenue nearly 3x of domestic patients, making medical tourism an important contributor to future profitability

* Each new IVF hub requires only about INR 2.5 Cr of investment; nearly INR 1.5 Cr allocated for specialised equipment and the remainder for interiors. Since the company designs laboratories internally, it saves substantial capital as compared to outsourcing lab construction.

Operational Performance

* The company delivers ~58% first-attempt IVF success rates and ~85% cumulative pregnancy success within three treatment cycles, placing it among the leading fertility providers globally and creating a strong competitive advantage through clinical excellence

* Over several years, the management developed detailed SOPs covering every aspect of IVF operations, including clinical protocols, embryology, laboratory design, nursing, counselling, administration, and housekeeping. This standardization allows consistent outcome across centers.

* The management highlighted that newly-established IVF hubs generally achieve operational breakeven within three to six months, requiring only about five treatment cycles monthly to cover operating expenses, making expansion relatively low-risk

* Unlike traditional IVF chains which invest heavily in every center, spoke locations require negligible capital expenditure. Existing gynaecologists are trained under company protocols and operate as exclusive fertility partners, allowing rapid market penetration, employing minimal investment

* Nearly 97% of business is generated directly from patients (B2C) rather than doctor referrals. This reduces dependency on referral incentives and creates a stronger, more sustainable brand with healthier operating margin

* Every patient follows a structured journey involving counsellors, fertility experts, finance counsellors, pharmacy support, and continuous engagement.

* AI-based IVF Technologies: The company recently introduced advanced AI tools named SID and ERICA, which assist embryologists in selecting the highest-quality sperm and embryos. Early implementation has already demonstrated an estimated 8–10% improvement in IVF success rate

* The management claims to be among the first fertility chains in India and Asia to deploy these advanced AI technologies commercially, creating a meaningful technological differentiation over competitors

For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131